STERIS plc (Ireland) ($STE) Stock Forecast: Up 5.1% Today

What is STERIS plc (Ireland)?

STERIS (STE) is a company specializing in medical equipment and devices, with a focus on sterility assurance and healthcare solutions. The stock had a strong bullish movement today.

Why is STERIS plc (Ireland) going up?

STE stock is up 5.1% on May 12, 2026 18:21

• STE shares surged by 3.4% after the company's fiscal 2026 fourth-quarter and full-year update, which included a new $1 billion share repurchase program and an optimistic fiscal 2027 outlook, projecting adjusted EPS of $11.10–$11.30.
• Despite a slight miss in EPS for Q4 2026, the positive revenue growth, strategic expansions, and increased guidance for FY 2027 instilled confidence in investors, leading to the bullish movement in the stock.
• The insider trading activity, mixed movements by institutional investors, and purchases of STE stock by Congress members also contributed to the positive sentiment surrounding the company's future prospects.
• The news of Representative Gilbert Ray Cisneros, Jr. acquiring shares of STERIS plc further added to the positive market sentiment, reflecting confidence in the company's growth trajectory and potential.

STE Price Chart

STE Technical Analysis

STE News

STERIS climbs after full-year results, new $1B buyback, and upbeat FY2027 outlook

STERIS (STE) shares rose 3.4% following its fiscal 2026 fourth-quarter and full-year update, which included a new $1 billion share repurchase program and an optimistic fiscal 2027 outlook, projecting adjusted EPS of $11.10–$11.30. The company reported fiscal 2026 revenue of $5.9 billion, a 9% year-over-year increase, and announced plans for a new sterility assurance manufacturing plant. Insider trading activity showed sales, while institutional investors had mixed movements, and Congress members made purchases of STE stock.

https://www.quiverquant.com/news/STERIS+climbs+after+full-year+results%2C+new+%241B+buyback%2C+and+upbeat+FY2027+outlook

Earnings call transcript: STERIS Q4 2026 revenue beats, EPS misses slightly

STERIS plc reported mixed Q4 2026 results, with revenue of $1.6 billion exceeding forecasts but EPS of $2.83 slightly missing expectations. Despite solid year-over-year revenue growth and strategic expansions, the stock declined in premarket trading due to investor concerns over the EPS miss and continued cost pressures. The company provided optimistic FY 2027 guidance, anticipating revenue growth of 7-8% and EPS of $11.10-$11.30, while outlining capital allocation plans including a new $1 billion share buyback authorization.

https://ca.investing.com/news/stock-market-news/earnings-call-transcript-steris-q4-2026-revenue-beats-eps-misses-slightly-93CH-4630956

Argus Adjusts Price Target on Stryker to $350 From $435, Maintains Buy Rating

Argus has adjusted its price target for Stryker (SYK) to $350 from $435, while maintaining a Buy rating on the stock. This news, published on May 12, 2026, reflects a revised outlook on the medical equipment and devices company. Stryker specializes in surgical equipment, neurotechnology, and orthopedic implants, with significant sales in the United States and Europe.

https://www.marketscreener.com/news/argus-adjusts-price-target-on-stryker-to-350-from-435-maintains-buy-rating-ce7f5bdedd89f127

Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of STERIS plc (NYSE:STE)

Representative Gilbert Ray Cisneros, Jr. recently purchased shares of STERIS plc (NYSE:STE) valued between $1,001 and $15,000. This transaction was part of several recent trades by the Representative, including purchases in Revvity, LPL Financial, FirstService, Wayfair, DoorDash, Sensata Technologies, and Veralto, and sales in Flex and SS&C Technologies. STERIS plc recently reported quarterly earnings that missed estimates but raised its fiscal 2027 guidance, reflecting confidence in its growth trajectory.

https://www.marketbeat.com/instant-alerts/rep-gilbert-ray-cisneros-jr-acquires-shares-of-steris-plc-nyseste-2026-05-12/

Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of STERIS plc (NYSE:STE)

Representative Gilbert Ray Cisneros, Jr. recently purchased between $1,001 and $15,000 worth of STERIS plc (NYSE:STE) shares on May 1st. This transaction comes as STERIS reported quarterly EPS of $2.83, slightly missing expectations, with revenue of $1.59 billion, increasing 6.7% year-over-year. The company also raised its FY 2027 EPS guidance and declared a quarterly dividend of $0.63 per share.

https://www.marketbeat.com/instant-alerts/rep-gilbert-ray-cisneros-jr-purchases-shares-of-steris-plc-nyseste-2026-05-12/

Trending Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 5.1% Today

STERIS plc (Ireland) ($STE) Stock Forecast: Up 5.1% Today

Intel Corporation ($INTC) Stock Forecast: Down 7.9% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 7.2% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 12.4% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Down 9.9% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Down 5.2% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.7% Today

Circle Internet Group ($CRCL) Stock Forecast: Down 5.5% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 6.0% Today

STERIS plc (Ireland) Price History

12.04.2026 - STE Stock was up 2.5%

• Significant upward movement was observed in the stock of STERIS plc (STE) today.
• Positive market sentiment towards medical equipment companies, including STERIS, could be related to adjustments in Stryker's (SYK) price target by Argus.
• Recent acquisitions of STERIS plc shares by Representative Gilbert Ray Cisneros, Jr. and the company's strong quarterly earnings exceeding revenue expectations and raising FY 2027 guidance likely supported the bullish trend.
• STERIS's robust fourth-quarter revenue surpassing analyst predictions and the company's enhanced fiscal forecast for 2027 also contributed to the stock's positive market performance.

25.01.2026 - STE Stock was up 1.0%

• The bullish movement in STE's stock price could be attributed to the positive outlook for the NPWT market. Given the projected significant growth of the global NPWT market due to increasing demand for advanced wound healing technologies, investors might view STE as well-positioned to benefit from this trend.
• The suggestion that STE is a better investment option compared to Abbott Laboratories could have also boosted investor confidence in the company's growth potential and valuation.
• Overall, the combination of favorable market dynamics in the NPWT sector and comparative analysis against peers like ABT might have driven the bullish movement in STE's stock price today.

25.01.2026 - STE Stock was up 0.9%

• The bullish movement in STERIS plc (STE) stock today can be attributed to a combination of factors:
• Strong financial performance: STERIS reported a significant year-over-year revenue increase in Q3, along with positive earnings per share and the issuance of FY2026 guidance, indicating a healthy financial outlook.
• Institutional investor activity: The increase in stake by Dana Investment Advisors Inc. and the continued interest from Generation Investment Management LLP signal confidence in the company's future prospects.
• Industry growth potential: The projected growth in the Japan Hospital Drug Waste Management Market, where STERIS operates, suggests a favorable market environment with opportunities for expansion and revenue growth.
• Analyst sentiment: Despite recent stock price fluctuations, analysts maintain a "Moderate Buy" rating on STERIS with a target price above the current valuation, indicating positive expectations for the stock's performance.

05.01.2026 - STE Stock was down 8.5%

• Despite exceeding revenue forecasts and demonstrating robust revenue growth, STERIS witnessed a downward trend in its stock performance.
• The stock's decline could potentially be linked to a slight slowdown in projected revenue growth, raising investor concerns about future prospects.
• Additionally, challenges related to increased tariff pressures may have further dampened investor confidence in the stock's outlook.
• In summary, STERIS continues to uphold a positive market sentiment and strong operational performance. Nevertheless, external factors such as tariff-related uncertainties and growth deceleration might have influenced the recent bearish movement in the stock price.

05.01.2026 - STE Stock was down 8.6%

• Despite reporting strong revenue growth and meeting bottom-line consensus estimates, STE's stock dipped in after-market trading due to investor concerns over the contraction in gross margins.
• The reaffirmation of a Market Outperform rating and a $280.00 price target post the earnings report indicates a positive outlook on STE's performance, but this might not have been enough to offset the margin contraction worries.
• A Hold rating maintained by an analyst could have also contributed to the bearish movement, as it may have raised doubts among investors about the company's future growth potential.
• The slight deceleration in projected revenue growth, despite strong sales performance and operating margin growth, could have added to the negative sentiment surrounding STE's stock today.

06.10.2025 - STE Stock was up 6.6%

• STE stock saw significant bullish activity today.
• Surpassing Q2 earnings and revenue projections signals robust financial results for the company.
• A noteworthy 10% rise in total revenue for the second quarter of fiscal 2026 highlights favorable growth prospects.
• Positive sentiments from analysts and investors regarding STE's future performance are bolstering investor trust in the stock.

05.00.2026 - STE Stock was up 2.2%

• Harvey Investment Co. LLC increasing its stake in STERIS plc by 17.1% indicates confidence in the company's future growth prospects, contributing to the bullish movement.
• The positive sentiment from analysts and institutional investors, coupled with STERIS exceeding earnings estimates and providing strong guidance, likely boosted investor confidence in the stock.
• While Pacer Advisors Inc. reducing its stake may have initially caused some selling pressure, the overall market sentiment remained positive due to the company's solid financial performance and essential services in the healthcare sector.
• STERIS's stability and long-term growth potential positioned the stock as an attractive option for investors seeking reliability amidst market volatility, further supporting its bullish movement.

12.04.2026 - STE Stock was up 5.1%

• STE shares surged by 3.4% after the company's fiscal 2026 fourth-quarter and full-year update, which included a new $1 billion share repurchase program and an optimistic fiscal 2027 outlook, projecting adjusted EPS of $11.10–$11.30.
• Despite a slight miss in EPS for Q4 2026, the positive revenue growth, strategic expansions, and increased guidance for FY 2027 instilled confidence in investors, leading to the bullish movement in the stock.
• The insider trading activity, mixed movements by institutional investors, and purchases of STE stock by Congress members also contributed to the positive sentiment surrounding the company's future prospects.
• The news of Representative Gilbert Ray Cisneros, Jr. acquiring shares of STERIS plc further added to the positive market sentiment, reflecting confidence in the company's growth trajectory and potential.